MicroRNA-107 promotes proliferation of gastric cancer cells by targeting cyclin dependent kinase 8

Diagnostic Pathology

Wen-ping Lv¹  Quan-jiang Deng¹  Chao Liu¹  Bin Lin¹  Gui-liang Ma¹  Xu-hui Ma¹  Yan-qiang Song¹ 

[1] Department of general surgery, Qingdao Municipal Hospital (East), Medical College of Qingdao University, No.5 Donghai Middle Road, Qingdao 266071, People¿s Republic of China

关键词: Gastric cancer;    CDK8;    Proliferation;    MiRNA-107;   

Others  :  1149909
DOI  :  10.1186/s13000-014-0164-1

 received in 2014-07-21, accepted in 2014-08-16,  发布年份 2014

【 摘 要 】

Background

The biological processes and molecular mechanisms underlying miR-107 remain unclear in gastric cancer(GC). In this study, we aimed to investigate the expression, biological functions and mechanisms of miR-107 in GC.

Methods

Quantitative real-time RT-PCR was used to test miR-107 expression. MTT and colony formation assays were conducted to explore the potential function of miR-107 in human GC cell line SGC7901. The target gene was determined by bioinformatic algorithms, dual luciferase reporter assay, RT-PCR and Western blot.

Results

Expression of miR-107 was significantly elevated in GC cell line than that in gastric epithelial cell line(p?=?0.012). We found that miR-107 inhibitor transfection significantly decreased the proliferation of GC cell line, and clone formation rate of miR-107 inhibitor transfected group was significantly lower than that of control group. Luciferase assays using a reporter carrying a putative miR-107 target site in the 3?untranslated region (3?-UTR) of cyclin dependent kinase 8 (CDK8) revealed that miR-107 directly targets CDK8. The expression level of CDK8 mRNA and protein in miR-107 inhibitor transfected GC cell line was significantly decreased compared with control group.

Conclusion

Our findings indicate that miR-107 is upregulated in GC and affects the proliferation of GC cells, partially through the regulation of CDK8.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_164 webcite

【 授权许可】

   
2014 Song et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
• [2]Delaunoit T: Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res 2011, 3:257-266.
• [3]Kwak PB, Iwasaki S, Tomari Y: The microRNA pathway and cancer. Cancer Sci 2010, 101(11):2309-2315.
• [4]Ambros V: The functions of animal microRNAs. Nature 2004, 431(7006):350-355.
• [5]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
• [6]He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005, 102(52):19075-19080.
• [7]Brennecke J, Cohen SM: Towards a complete description of the microRNA complement of animal genomes. Genome Biol 2003, 4(9):228. BioMed Central Full Text
• [8]Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299(4):425-436.
• [9]Li XY, Luo QF, Wei CK, Li DF, Li J, Fang L: MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer. Int J Clin Exp Med 2014, 7(1):32-40.
• [10]He J, Zhang W, Zhou Q, Zhao T, Song Y, Chai L, Li Y: Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell Biol 2013, 45(9):1962-1973.
• [11]Sharma P, Saraya A, Gupta P, Sharma R: Decreased levels of circulating and tissue miR-107 in human esophageal cancer. Biomarkers 2013, 18(4):322-330.
• [12]Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, Shyy JY, Liang JT: Chen RH: miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 2012, 72(14):3631-3641.
• [13]Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R: Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol Rep 2012, 27(6):1759-1764.
• [14]Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, Soukup TM, Roose-Girma M, Blackwood EM, Firestein R: CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res 2012, 72(8):2129-2139.
• [15]Morris EJ, Ji JY, Yang F, Di Stefano L, Herr A, Moon NS, Kwon EJ, Haigis KM, Naar AM, Dyson NJ: E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 2008, 455(7212):552-556.
• [16]Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs CS, Loda M, Shivdasani RA, Meyerson M, Hahn WC: CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008, 455(7212):547-551.
• [17]Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838.
• [18]Feng L, Xie Y, Zhang H: Wu Y: miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol 2012, 29(2):856-863.
• [19]Li F, Liu B, Gao Y, Liu Y, Xu Y, Tong W, Zhang A: Upregulation of microRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1. FEBS Lett 2014, 588(4):538-544.
• [20]Sharma PS, Sharma R, Tyagi R: Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr Cancer Drug Targets 2008, 8(1):53-75.
• [21]Senderowicz AM, Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000, 92(5):376-387.